Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
Tango Therapeutics (TNGX) Stock Price & Analysis
65 Followers
TNGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.88 - $13.03
Previous Close$9.96
Volume449.06K
Average Volume (3M)665.51K
Market Cap
$1.06B
Enterprise Value$766.22M
Total Cash (Recent Filing)$336.88M
Total Debt (Recent Filing)$38.92M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 06, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding106,846,262
10 Day Avg. Volume1,055,219
30 Day Avg. Volume665,511
Standard Deviation0.30
R-Squared0.03
Alpha0.00949
Financial Highlights & Ratios
Price to Book (P/B)4.26
Price to Sales (P/S)198.70
Price to Cash Flow (P/CF)-9.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.30
Enterprise Value/Gross Profit20.98
Enterprise Value/Ebitda-7.32
Forecast
1Y Price Target
$14.00Price Target Upside39.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Tango Therapeutics News
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst reiterates a Buy rating while adjusting the 12-month price target to $13 per share.
Clinical TrialsThe company noted that dose expansion for TNG462 (next-gen PRMT5i) would be initiating, suggesting positive progress with this molecule.
Financial PerformanceTango's cash runway now extends into 2027 due to the discontinuation of TNG348.
Bears Say
CompetitionCompetitor agent IDE397 delivers solid initial results in MTAP-deleted urothelial and lung cancer.
Financial PerformanceReturn on Equity TTM (%) -45.41
Product DevelopmentTango Therapeutics announced that it is discontinuing development of TNG348 due to Grade 3/4 liver function abnormalities being observed in patients.
---
Ownership Overview
52.56% Insiders
11.59% Mutual Funds
6.91% Other Institutional Investors
28.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $2.88 and its highest was $13.03 in the past 12 months.
What is Tango Therapeutics’s market cap?
Currently, no data Available
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 10 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on May 08, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.04.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -$0.35.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 106,846,260 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 0.764%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Among the largest hedge funds holding Tango Therapeutics’s share is Deerfield Management Company, LP. It holds Tango Therapeutics’s shares valued at 12M.
---
Tango Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (39.72% Upside)
$14.00 (39.72% Upside)
Blogger Sentiment
Neutral
TNGX Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
181.35%
12-Months-Change
Fundamentals
Return on Equity
-45.41%
Trailing 12-Months
Asset Growth
0.61%
Trailing 12-Months
Company Description
Tango Therapeutics
BCTG Acquisition Corp is a blank check company.
---
TNGX Stock 12 Month Forecast
Average Price Target
$14.00
▲(39.72% Upside)
Technical Analysis
Best Analysts Covering TNGX
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+25.93%
reiterated a buy rating 18 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +25.93% per trade.
---